7 results on '"Lindner, Alfred"'
Search Results
2. Coping as a resource to allow for psychosocial adjustment in fatal disease: results from patients with amyotrophic lateral sclerosis.
- Author
-
Finsel, Julia, Rosenbohm, Angela, Peter, Raphael S., Bäzner, Hansjörg, Börtlein, Axel, Dempewolf, Silke, Schabet, Martin, Hecht, Martin, Kohler, Andreas, Opherk, Christian, Nägele, Andrea, Sommer, Norbert, Lindner, Alfred, Rothenbacher, Dietrich, Ludolph, Albert C., Nagel, Gabriele, and Lulé, Dorothée E.
- Subjects
AMYOTROPHIC lateral sclerosis ,PSYCHOLOGICAL adaptation ,FAILURE (Psychology) ,FEAR of failure ,PATIENTS' attitudes - Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal disorder, which imposes a severe emotional burden on patients. Appropriate copingmechanisms may alleviate this burden and facilitate wellbeing, with social support known to be a successful coping strategy. This observational study aimed to determine the interplay of general coping traits of hope for success and fear of failure, coping behavior of social activity, and patients' wellbeing. Methods: In this cross-sectional study, patients with ALS from a clinical-epidemiological registry in Southwestern Germany were interviewed regarding coping traits (achievement-motivated behavior: hope for success and fear of failure), coping behavior of social activity, and psychosocial adjustment, determined using measures of depressiveness, anxiety [both measured by Hospital Anxiety and Depression Scale (HADS)], and quality of life [Anamnestic Comparative Self-Assessment (ACSA)]. Demographics, clinical [ALS Functional Rating Scale revised version (ALSFRS-R)], and survival data were recorded. Results: A total of 868 patients [60.70% male patients, mean age: 64.70 (±10.83) years, mean ALSFRS-R: 37.36 ± 7.07] were interviewed. Anxiety in patients was found to be associated with a high fear of failure. In contrast, a generally positive attitude in patients exemplified in high hopes for success was associated with better wellbeing. Finally, coping behavior of social activity explained up to 65% of the variance of depressiveness among the patients with ALS. Conclusion: In this study, we present evidence that the wellbeing of patients with ALS is not an immediate fatalistic consequence of physical degradation but rather determined by coping traits and behavior, which may be trained to substantially increase the wellbeing of patients with ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Population-based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
- Author
-
Witzel, Simon, primary, Huss, André, additional, Nagel, Gabriele, additional, Rosenbohm, Angela, additional, Rothenbacher, Dietrich, additional, Peter, Raphael, additional, Baezner, Hansjörg, additional, Boertlein, Axel, additional, Dempewolf, Silke, additional, Schabet, Martin, additional, Hecht, Martin, additional, Kohler, Andreas, additional, Opherk, Christian, additional, Naegele, Andrea, additional, Sommer, Norbert, additional, Lindner, Alfred, additional, Alexudis, Christoforos, additional, Bachhuber, Franziska, additional, Halbgebauer, Steffen, additional, Brenner, David, additional, Ruf, Wolfgang, additional, Weiland, Ulrike, additional, Mayer, Benjamin, additional, Schuster, Joachim, additional, Dorst, Johannes, additional, Tumani, Hayrettin, additional, and Ludolph, Albert, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Population-based Evidence for Using Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
- Author
-
Witzel, Simon, primary, Huss, André, additional, Nagel, Gabriele, additional, Rosenbohm, Angela, additional, Rothenbacher, Dietrich, additional, Peter, Raphael, additional, Baezner, Hansjörg, additional, Boertlein, Axel, additional, Dempewolf, Silke, additional, Schabet, Martin, additional, Hecht, Martin, additional, Kohler, Andreas, additional, Opherk, Christian, additional, Naegele, Andrea, additional, Sommer, Norbert, additional, Lindner, Alfred, additional, Alexudis, Christoforos, additional, Bachhuber, Franziska, additional, Halbgebauer, Steffen, additional, Brenner, David, additional, Ruf, Wolfgang, additional, Weiland, Ulrike, additional, Mayer, Benjamin, additional, Schuster, Joachim, additional, Dorst, Johannes, additional, Tumani, Hayrettin, additional, and Ludolph, Albert, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Life Course of Physical Activity and Risk and Prognosis of Amyotrophic Lateral Sclerosis in a German ALS Registry
- Author
-
Rosenbohm, Angela, Peter, Raphael, Dorst, Johannes, Kassubek, Jan, Rothenbacher, Dietrich, Nagel, Gabriele, Ludolph, Albert C., Andres, Frank, Arnold, Guy, Baier, Hartmut, Baezner, Hansjoerg, Beattie, James, Behne, Friedrich, Bengel, Dietmar, Boertlein, Axel, Vera, Bracknies, Alber, Burkhard, Buttmann, Mathias, Dempewolf, Silke, Dettmers, Christian, Freund, Wolfgang, Gasser, Thomas, Gold, Hans-Juergen, Hamann, Gerhard, Hecht, Martin, Heimbach, Bernhard, Herting, Birgit, Huber, Roman, Huelser, Paul-Juergen, HuberHartmann, Karlheinz, Jüttler, Eric, Kaspar, Attila, Kern, Rolf, Kimmig, Hubert, Christof, Klötzsch, Chatzikonstantinou, Anastasios, Klopstock, Thomas, Kohler, Andreas, Lichy, Christoph, Lindner, Alfred, Lingor, Paul, Lulé, Dorothee, Metrikat, Jens, Meudt, Oliver, Meyer, Andreas, Naegele, Andrea, Naumann, Markus, Neher, Klaus-Dieter, Neuhaus, Oliver, Neusch, Clemens, Niehaus, Ludwig, Raape, Jan, Ratzka, Peter, Reinhard, Matthias, Rothmeier, Johann, Sabolek, Michael, Schabet, Martin, SchaeffVogelsang, MDMario, Schell, Caroline, Schell, Caroline, Schweigert, Barbara, Sommer, Norbert, Stroick, Mark, Synofzik, Mathis, Tumani, Hayrettin, Volkmann, Jens, Weiler, Markus, Wick, Wolfgang, Opherk, Christian, Weiller, Cornelius, Zeller, Daniel, Baumgärtner, Jessica, Born, Christoph, Bürgy, Martin, Connemann, Bernhard, Etzersdorfer, Elmar, Friederich, Hubertus, Gahr, Maximilian, Gogolkiewicz, Alex, Greber, Ralf, Gebhardt, Jochen, Grunze, Heinz, Henkel, Karsten, Hewer, Walter, Raether, Andreas, Joos, Andreas, Köhler, Matthias, Kozian, Ralf, Laske, Christoph, Michaelides, Alexandros, Munk, Matthias, Niestroj, Andreas, Schmauss, Max, Schmauss, Max, SchoenebergerStroick, Katrin, Schoerner, Kai-Uwe, Spannhorst, Stefan, Steber, Raimund, Thomas, Christine, and Vasic, Nenad
- Published
- 2021
- Full Text
- View/download PDF
6. Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
- Author
-
Witzel, Simon, Huss, André, Nagel, Gabriele, Rosenbohm, Angela, Rothenbacher, Dietrich, Peter, Raphael S., Bäzner, Hansjörg, Börtlein, Axel, Dempewolf, Silke, Schabet, Martin, Hecht, Martin, Kohler, Andreas, Opherk, Christian, Naegele, Andrea, Sommer, Norbert, Lindner, Alfred, Alexudis, Christoforos, Bachhuber, Franziska, Halbgebauer, Steffen, and Brenner, David
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *BODY mass index , *BIOMARKERS , *KIDNEY physiology , *CYTOPLASMIC filaments - Abstract
Objective Methods Results Interpretation Neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital‐based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical trials. This study extends their evaluation to a population level, with the aim of advancing their full establishment and assessing the transferability of biomarker findings from controlled cohorts to real‐world ALS populations.We measured serum NfL and pNfH levels in all ALS patients (n = 790) and general population controls (n = 570) with available baseline samples participating in the epidemiological ALS Registry Swabia, providing platform‐specific (ELLA™) reference data and Z‐scores for controls, as well as reference data, disease‐specific Z‐scores and longitudinal data in ALS. We evaluated the diagnostic and prognostic utility of neurofilaments and quantified the impact of ALS‐related factors and non‐ALS confounders.Neurofilaments showed high diagnostic and prognostic utility at the population level, with NfL superior to pNfH. The novel concept of a population‐based ALS Z‐score significantly improved the prognostic utility compared to absolute raw values. Both biomarkers increased more strongly with age in controls than in ALS, and age adjustment improved diagnostic accuracy. Our data show that disease progression rates, ALS phenotype, body mass index (BMI), and renal function need to be considered when interpreting neurofilament levels; longitudinal neurofilament levels were generally stable in individual patients, especially when adjusted for age and baseline levels.Population‐based assessment enhances the utility of particularly serum NfL as a diagnostic and prognostic biomarker in ALS and improves the translation of findings from controlled cohorts to real‐world populations. ANN NEUROL 2024 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.
- Author
-
Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, Gawaz M, Tünnerhoff J, Bombach P, Nägele T, Klose U, Aidery P, Groga-Bada P, Kraft A, Hoffmann F, Hobohm C, Naupold K, Niehaus L, Wolf M, Bäzner H, Liman J, Wachter R, Kimmig H, Jung W, Huber R, Feurer R, Lindner A, Althaus K, Bode FJ, Petzold GC, Nguyen TN, Mac Grory B, Schrag M, Purrucker JC, Zuern CS, Ziemann U, and Poli S
- Subjects
- Humans, Aspirin, Double-Blind Method, Embolic Stroke, Pyrazoles, Pyridones, Stroke prevention & control
- Abstract
BACKGROUND: Rivaroxaban and dabigatran were not superior to aspirin in trials of patients with embolic stroke of undetermined source (ESUS). It is unknown whether apixaban is superior to aspirin in patients with ESUS and known risk factors for cardioembolism. METHODS: We conducted a multicenter, randomized, open-label, blinded-outcome trial of apixaban (5 mg twice daily) compared with aspirin (100 mg once daily) initiated within 28 days after ESUS in patients with at least one predictive factor for atrial fibrillation or a patent foramen ovale. Cardiac monitoring was mandatory, and aspirin treatment was switched to apixaban in case of atrial fibrillation detection. The primary outcome was any new ischemic lesion on brain magnetic resonance imaging (MRI) during 12-month follow-up. Secondary outcomes included major and clinically relevant nonmajor bleeding. RESULTS: A total of 352 patients were randomly assigned to receive apixaban (178 patients) or aspirin (174 patients) at a median of 8 days after ESUS. At 12-month follow-up, MRI follow-up was available in 325 participants (92.3%). New ischemic lesions occurred in 23 of 169 (13.6%) participants in the apixaban group and in 25 of 156 (16.0%) participants in the aspirin group (adjusted odds ratio, 0.79; 95% confidence interval, 0.42 to 1.48; P=0.57). Major and clinically relevant nonmajor bleeding occurred in five and seven participants, respectively (1-year cumulative incidences, 2.9 and 4.2; hazard ratio, 0.68; 95% confidence interval, 0.22 to 2.16). Serious adverse event rates were 43.9 per 100 person-years in those given apixaban and 45.7 per 100 person-years in those given aspirin. The Apixaban for the Treatment of Embolic Stroke of Undetermined Source trial was terminated after a prespecified interim analysis as a result of futility. CONCLUSIONS: Apixaban treatment was not superior to cardiac monitoring-guided aspirin in preventing new ischemic lesions in an enriched ESUS population. (Funded by Bristol-Myers Squibb and Medtronic Europe; ClinicalTrials.gov number, NCT02427126.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.